Drug Profile
Coronavirus vaccine - ID Biomedical
Alternative Names: SARS vaccine - ID BiomedicalLatest Information Update: 10 Mar 2008
Price :
$50
*
At a glance
- Originator ID Biomedical Corporation
- Class COVID-19 vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Severe acute respiratory syndrome
Most Recent Events
- 10 Mar 2008 No development reported - Preclinical for Severe acute respiratory syndrome in Canada (Intranasal)
- 08 Dec 2005 ID Biomedical Corporation has been acquired by GlaxoSmithKline
- 13 Oct 2004 Preclinical trials in Severe acute respiratory syndrome in Canada (Intranasal)